Physician profile
Ahmet Sevimli
NPI 1912096629
$3,151.04
in general payments reported to CMS, 2019-2025
21 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.85 · 2022: $19.69 · 2023: $15.60 · 2024: $1,475 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.24 |
| Education | $106.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $673.39 | 2024-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $499.32 | 2024-2025 | Tarpeyo |
| Amgen INC. | $442.89 | 2024-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $204.05 | 2024-2025 | |
| Vantive US Healthcare LLC | $190.98 | 2025 | Renal - Pd |
| Travere Therapeutics, INC. | $169.49 | 2024-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $149.96 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $142.28 | 2024-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $125.94 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $105.48 | 2024-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $86.79 | 2022-2025 | Lupkynis |
| Ardelyx, INC. | $82.91 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $72.67 | 2024 | Purified Cortrophin Gel |
| Renalytix Ai, INC. | $47.45 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Glaxosmithkline, LLC. | $29.86 | 2024 | Benlysta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.80 | 2024 | Jardiance |
| Nxstage Medical, INC. | $23.85 | 2019 | |
| Novo Nordisk INC | $23.34 | 2025 | Ozempic |
| Genzyme Corporation | $20.90 | 2024 | |
| Baxter Healthcare | $15.60 | 2023 | Renal - Pd |
| Lilly USA, LLC | $15.09 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmet Sevimli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.